Human Fertilisation and Embryology Act (HFE Act)

The Human Fertilisation and Embryology Act 1990 (as substantially amended by the Human Fertilisation and Embryology Act 2008) is the UK statute that makes it a criminal offence to create, keep, or use a human embryo outside the body, or to carry out licensable fertility treatment or embryo research, except under a licence granted by a dedicated statutory regulator. It established that regulator — the Human Fertilisation and Embryology Authority (HFEA) — and it is the legal instrument, not the HFEA itself, that defines what research on human embryos is lawful in Great Britain, under what conditions, and for how long an embryo may be kept or used. The 1990 Act followed the 1984 Warnock Report and received Royal Assent that year; the 2008 Act updated it for developments the original text did not anticipate — human admixed embryos, mitochondrial donation regulation-making powers, and parenthood provisions unrelated to research — without replacing its core licensing architecture.

The licensing requirement and the three licence categories

Section 3(1) of the Act prohibits bringing about the creation of an embryo, or keeping or using one, “except in pursuance of a licence.” The HFEA issues three categories of licence under this framework: treatment licences (fertility clinics providing IVF, donor insemination, and related services), storage licences (freezing and holding gametes and embryos), and research licences (creating, keeping, or using embryos for a permitted research purpose). A single centre can hold more than one category. Research licences are the ones of direct relevance to research administration: they are granted and renewed by the HFEA’s Licence Committee, typically run for up to three years, and are conditional on the centre also holding the separate ethical opinion research on human subjects generally requires — HFEA licensing and research ethics committee review are two distinct approvals that both apply to the same project, the same two-track pattern already documented for the Human Tissue Act’s HTA-licence-plus-REC-opinion structure.

Schedule 2: the permitted purposes for a research licence

A research licence cannot be granted for any purpose a researcher happens to propose — the Act restricts it to a closed list. Schedule 2, paragraph 3A(2) permits research licensing only where the HFEA is satisfied the research is necessary or desirable for one of these purposes:

• Increasing knowledge about the causes of congenital disease
• Increasing knowledge about the causes of miscarriage
• Developing more effective techniques of contraception
• Developing methods for detecting the presence of gene, chromosome, or mitochondrion abnormalities in embryos before implantation
• Increasing knowledge about the development of embryos
• Increasing knowledge about serious disease, or enabling any such knowledge to be applied in developing treatments for serious disease
• Promoting advances in the treatment of infertility

The Authority may also license activities that provide knowledge applicable to those purposes, or activities within purposes it specifies by regulations. The 2008 Act’s principal addition to this list was permitting the creation and use of human admixed embryos — embryos combining human and animal genetic material for research, most commonly to work around the shortage of human eggs available for techniques such as somatic cell nuclear transfer — for the same closed set of Schedule 2 purposes, and specifically excluded them from ever being placed in a woman or allowed to develop beyond 14 days.

The 14-day limit

Section 3(3)-(4) of the Act sets the outer statutory boundary for all licensed embryo research: no licence can authorise keeping or using an embryo after the appearance of the primitive streak, and the Act deems the primitive streak to have appeared “not later than the end of the period of 14 days” from the day the embryo was created, excluding any time the embryo was stored. In practice this means a licensed embryo cannot be cultured past 14 days regardless of what stage of development it has actually reached — the limit is a bright-line statutory cut-off, not a biological observation made case by case. Until 2016, the practical constraint rarely bound, because standard embryo-culture technique could not keep an embryo alive in vitro much past 9-10 days; refinements since then have made reaching closer to the statutory limit routine, and the “14-day rule” (a limit adopted in comparable form by several other jurisdictions and by the International Society for Stem Cell Research’s own guidelines) has become a live subject of bioethics and policy debate about whether the statutory boundary should move, rather than a purely theoretical ceiling.

What the Act does not cover

The Act’s licensing regime is specific to embryos and, for research and treatment purposes, gametes — it does not extend to human tissue or cells more generally, which fall instead under the Human Tissue Act 2004 (itself expressly excluding gametes and embryos outside the body from its own scope, to avoid the two statutes overlapping). It also does not itself resolve every downstream regulatory question a research project involving embryos raises: data protection for identifiable donor/patient information is separately governed by UK GDPR and the Human Fertilisation and Embryology (Disclosure of Information for Research Purposes) Regulations, and broader research-ethics review for the human participants donating gametes or embryos still runs through the standard REC process. A project can therefore need an HFEA research licence, REC ethical approval, and a data-protection basis for handling identifiable donor information as three separate, concurrently-tracked compliance items.

Practical implications for research administrators

• Confirm early whether a project actually creates, keeps, or uses a human embryo (or human admixed embryo) outside the body — research using only gametes that are never combined to form an embryo, or using cell lines already derived from a licensed source, may sit outside the Act’s own licensing trigger even though downstream ethics and data-protection obligations still apply.
• Map any embryo-research proposal against the Schedule 2 closed list before assuming it is licensable — a purpose that does not fit one of the seven categories (or a purpose the HFEA has separately specified by regulation) cannot be licensed no matter how scientifically sound it is.
• Treat the 14-day statutory limit as an absolute research-design constraint, not a target: any protocol culturing embryos for research must build in enough margin that normal variation in development timing cannot push the work past day 14.
• Track HFEA research-licence status, REC/ethics approval, and the data-protection basis for donor information as three separate compliance records for the same project, the way HTA-licensing and REC approval are tracked separately for human tissue research.
• Distinguish the Act (the statute defining what is lawful) from the HFEA (the regulator that licenses and inspects against it) and the HFEA’s Code of Practice (the regulator’s operational guidance interpreting the Act’s requirements for licensed centres) — administrators dealing with a specific licensing question usually need the Code of Practice, not the Act’s bare statutory text.

Frequently asked questions

What is the Human Fertilisation and Embryology Act?

The UK statute (1990, as amended by the 2008 Act) that prohibits creating, keeping, or using a human embryo outside the body except under a licence, establishes the HFEA as the licensing regulator, and sets the substantive limits — including the closed list of permitted research purposes and the 14-day limit on embryo culture — that any licence must operate within.

What did the 2008 Act change?

Among other changes unrelated to research licensing, the 2008 Act added human admixed embryos to the categories of embryo that can be created and used under a research licence for the same Schedule 2 purposes, gave the Secretary of State a regulation-making power later used to permit mitochondrial donation techniques, and updated parenthood provisions for treatment (not research) purposes. It kept the 1990 Act’s core licensing architecture and the 14-day limit unchanged.

What research purposes qualify for an HFEA research licence?

Schedule 2 restricts research licensing to seven purposes: knowledge of congenital disease, knowledge of miscarriage, more effective contraception, pre-implantation detection of gene/chromosome/mitochondrion abnormalities, knowledge of embryo development, knowledge of serious disease (or developing treatments for it), and advances in infertility treatment — plus any further purpose the HFEA specifies by regulation.

Is the 14-day rule set by the HFEA or by the Act itself?

By the Act itself, at section 3(3)-(4). The HFEA administers and enforces it through licence conditions and inspection, but the statutory 14-day limit is fixed in primary legislation, not something the regulator sets independently and could vary by itself.

How is this different from the Human Tissue Act?

The two statutes deliberately do not overlap: the Human Fertilisation and Embryology Act covers embryos and, for treatment/research purposes, gametes, licensed and inspected by the HFEA; the Human Tissue Act covers human tissue and cells generally, licensed and inspected by the separate Human Tissue Authority, and expressly excludes gametes and embryos outside the body from its own definition of regulated material.